Eugenia Yazlovitskaya
Faculty Member
Last active: 11/16/2017

Prolonged wild-type p53 protein accumulation and cisplatin resistance.

Yazlovitskaya EM, DeHaan RD, Persons DL
Biochem Biophys Res Commun. 2001 283 (4): 732-7

PMID: 11350044 · DOI:10.1006/bbrc.2001.4849

The major limitation for the chemotherapeutic use of DNA-damaging agent cisplatin is the development of resistance in initially responsive tumors. One of the main pathways regulating cell survival following DNA damage is the p53 pathway. In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21WAF-1 and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. A higher dose of cisplatin and a longer exposure time was required to achieve the same level of p53, p21WAF-1, and Mdm2 protein accumulation in the cisplatin-resistant CP70 cells versus cisplatin-sensitive A2780 cells. A significant difference between the two cell lines was observed in cisplatin-induced stabilization of p53 protein. The p53 half-life increased 31-fold in CP70 cells compared to only 6-fold in A2780 cells. In contrast, there was no difference in p21WAF-1 half-life between the two cell lines. These results demonstrate that in A2780 and CP70 cells resistance to cisplatin correlates with prolonged p53 protein stabilization and accumulation.

Copyright 2001 Academic Press.

MeSH Terms (14)

Adenocarcinoma Antineoplastic Agents Cisplatin Cyclin-Dependent Kinase Inhibitor p21 Cyclins Drug Resistance, Neoplasm Female Humans Nuclear Proteins Ovarian Neoplasms Proto-Oncogene Proteins Proto-Oncogene Proteins c-mdm2 Tumor Cells, Cultured Tumor Suppressor Protein p53

Connections (1)

This publication is referenced by other Labnodes entities: